Next-generation antibody therapeutics refer to the improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Next-generation antibody-based therapeutics overcome the limitations of monoclonal antibodies and feature enhancements to existing properties of therapeutic antibodies. Various biotechnology and biopharmaceutical companies are actively involved in development of next-generation Antibody Therapeutics, especially for cancer, autoimmune, and inflammatory diseases. Factors such as growing R&D activities, increasing prevalence of chronic diseases, technological advancements in antibody therapeutics, and rising healthcare expenditure are driving growth of the global next-generation antibody therapeutics market. However, stringent regulatory requirements, long approval times for new drugs, and high costs of next-generation antibody therapeutics are some of the key restraints for growth of the market.
Request for Sample Report: http://www.mrrse.com/sample/384
North America is the largest market for next-generation antibody therapeutics. The U.S. represents the largest market for next-generation antibody therapeutics in the region. This is due to the increasing prevalence of chronic diseases, rising healthcare expenditure, and growing R&D activities in the country.
This report provides in-depth analysis and estimation of the global next-generation antibody therapeutics market for the period 2015–2022, considering 2014 as the base year for calculations. In addition, data pertaining to current market dynamics, including market drivers, restraints, and strategic developments has been provided in the report. The next-generation antibody therapeutics market is categorized on the basis of technology, therapeutic application, and geography. Based on technology, the next-generation antibody therapeutics market is segmented into antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. In terms of therapeutic application, the market is segmented into oncology and autoimmune/inflammatory diseases. In the geographical analysis, the report identifies and analyzes market size and forecast for North America, Europe, Asia, and Rest of the World (RoW).
Browse Full Report with TOC: http://www.mrrse.com/next-generation-antibody-therapeutics-market
Some of the major players in the market are F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Seattle Genetics, Inc. ImmunoGen, Inc., Amgen, Inc., Biogen, Bayer AG, and Xencor, Inc. These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability and financial overview.
. About Us
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207
United States Telephone: +1-518-730-0559
Follow Us on LinkedIn-https://www.linkedin.com/company/mrrse
Follow Us On Twitter-https://twitter.com/MRRSEmrrse